OR Congressman Blumenauer urges DEA to clarify marijuana rescheduling plans

blumenauer stands against a cannabis backdrop, speaking passionately with a finger raised

Congressman Blumenauer’s Call to Provide Clear Timeline on Marijuana Rescheduling

Oregon’s relentless advocate for marijuana reform, Democratic congressman Earl Blumenauer, has taken action once more, wielding his pen like a beacon of transparency. In a missive dispatched on February 9, 2024, Blumenauer directed his concerns straight to the door of the Drug Enforcement Administration (DEA), urging for more lucidity regarding the agency’s intentions to reschedule marijuana.

As the illustrious founder and co-chair of the Congressional Cannabis Caucus, Blumenauer minced no words in his letter, expressing palpable frustration at the DEA’s opaque stance and lack of communicative prowess regarding the reevaluation of marijuana’s legal classification.

The wheels of change began to turn in August 2023 when the Department of Health and Human Services (HHS) formally proposed the migration of marijuana from the restrictive confines of Schedule I to the more lenient Schedule III of the Controlled Substances Act (CSA). This pivotal recommendation stemmed from a comprehensive scientific and medical evaluation conducted by the discerning minds at the Food and Drug Administration (FDA). Their verdict? Marijuana undeniably possesses a “currently accepted medical use in treatment in the United States” and squarely meets the criteria for a Schedule III classification.

Yet, despite this resounding endorsement, the DEA, holding the ultimate decision-making power, has remained tight-lipped. The clock has ticked past the 90-day threshold, eclipsing five months since the recommendation landed on their desks, yet still, the veil of silence persists.

In his epistolary plea, Blumenauer implored the DEA to expedite its deliberations, beckoning for a public update on the status of their review and a roadmap for forthcoming actions. He pressed for transparency, seeking elucidation on the causes behind the delay and the myriad factors shaping the agency’s decision-making calculus.

Enumerating the manifold benefits of rescheduling, Blumenauer highlighted the potential relief it could bring to the shoulders of the cannabis industry and consumers alike. Moving marijuana to Schedule III would alleviate the tax burdens shackling cannabis businesses and patrons, liberating them from the onerous strictures of the 280E provision of the Internal Revenue Code. Furthermore, it would pave the way for enhanced access to banking services, as the federal prohibition on financial transactions involving Schedule I substances would no longer loom ominously. In the realm of research and development, the shackles would loosen, fostering innovation and exploration with fewer regulatory hurdles obstructing progress. Quality control and safety standards would soar under the vigilant gaze of the FDA and other federal watchdogs.

Acknowledging the limitations of rescheduling, Blumenauer conceded that it wouldn’t single-handedly resolve the myriad challenges facing the cannabis industry and its patrons. The specter of federal-state law disparities, the yawning chasm of social equity, and the clarion call for comprehensive reform all loom large. Yet, he maintained that rescheduling represents a substantive stride forward, a tangible acknowledgment of marijuana’s scientific merit and societal relevance.

Blumenauer’s clarion call hasn’t echoed in solitude. In December 2023, a bipartisan coalition of 17 senators, marshaled by the likes of Cory Booker (D-NJ) and Rand Paul (R-KY), penned a missive akin to Blumenauer’s, beseeching the DEA to swiftly conclude its deliberations and consign the federal prohibition on marijuana to the annals of history.

Alas, the DEA’s response remains elusive, shrouded in ambiguity. While the agency has professed a commitment to evaluating the scientific and medical evidence on marijuana with due diligence, the timeline for its decision remains frustratingly obscured, leaving stakeholders in limbo.

As the cannabis community holds its breath, awaiting the clarion call from the DEA, Blumenauer’s missive stands as a testament to the relentless pursuit of transparency and reform, a beacon of hope in an uncertain landscape.


Trap Culture is the ultimate destination for cannabis enthusiasts who want to experience the best of Arizona’s cannabis culture. Whether you are looking for the hottest cannabis-friendly events, the latest news about everything from Blumenauer’s ongoing push for legalization, to trends in the cannabis industry, or the most exclusive and limited-edition products from the top brands in the market, Trap Culture has you covered. Visit our website to learn more about our events, our blog, and our store. Follow us on social media to stay updated on the latest news and promotions. Join the Trap Culture family and experience the most immersive and engaging cannabis-friendly social events in Arizona.